Market research
CYTK Cytokinetics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11B
- P/E ratio
- Not available
- Analyst target
- 109.9
- Dividend yield
- Not available
- Beta
- 0.38
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23282W6057
- Market cap
- 11B
- P/E ratio
- Not available
- Analyst target
- 109.9
- Dividend yield
- Not available
- Beta
- 0.38
About
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYTK discussion.
5 years, 4 months ago
Cytokinetics, Incorporated is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.9.
Cytokinetics, Incorporated's total revenue rose by 29.0% to $7M since the same quarter in the previous year.
Its net income has dropped by 43.4% to $-44M since the same quarter in the previous year.
Finally, its free cash flow grew by 323.9% to $46M since the same quarter in the previous year.
Based on the above factors, Cytokinetics, Incorporated gets an overall score of 3/5.